Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined therapy of alpha-1-antitrypsin and temporal t-cell depletion for preventing graft rejection

a technology of temporal t cell depletion and graft rejection, which is applied in the direction of antibody medical ingredients, immunological disorders, peptide/protein ingredients, etc., can solve the problems of delayed onset acute rejection or acute rejection of grafts, and achieve the effect of prolonging the survival of xenografts

Inactive Publication Date: 2015-01-08
BEN GURION UNIVERSITY OF THE NEGEV
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new treatment that can make pig organs last longer in humans. This treatment involves using two different types of drugs: AAT and T cell depletion. When used separately, each drug caused rejection of the graft. However, when the two drugs were used together, the pig organs stayed alive for much longer. This is a big improvement over current treatments, which have limited effectiveness or can cause rejection.

Problems solved by technology

As exemplified herein below, xenograft recipients were treated separately with AAT or T cell depletion, however, this resulted in acute rejection, or delayed-onset acute rejection of the graft, respectively.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined therapy of alpha-1-antitrypsin and temporal t-cell depletion for preventing graft rejection
  • Combined therapy of alpha-1-antitrypsin and temporal t-cell depletion for preventing graft rejection
  • Combined therapy of alpha-1-antitrypsin and temporal t-cell depletion for preventing graft rejection

Examples

Experimental program
Comparison scheme
Effect test

example 1

hAAT Monotherapy During Rat-to-Mouse Islet Transplantation

[0086]The initial dose for hAAT monotherapy (60 mg / kg from 1 day prior to transplantation) was selected from previous reports. In order to explore a higher impact monotherapy protocol, both a higher dose was examined (240 mg / kg) and an extended 10-day pretreatment protocol was tested. hAAT injections were repeated every 3 days in all experiments. A total of n (number in group)=6 mice were grafted under these conditions, including two recipients per modified protocol. In addition, n=6 mice were grafted with no added therapy, as control. As shown in FIG. 1A, neither of the three modified hAAT monotherapy protocols delayed islet xenograft rejection day (CT 10,11,12,13,15, 22 and hAAT 11, 12, 13, 14, 15, 24). The extended hAAT protocol is thereby used throughout the following studies.

[0087]Intragraft changes were examined (FIG. 1B-D). According to histology on day 7 post-transplantation (n=3 per group, representative images), inf...

example 2

DLN Molecular Profile During hAAT Monotherapy

[0089]In order to achieve a robust immune response, improve detection of changes in DLN, and achieve responses with low variability, skin xenotransplantation was performed. Treatment groups included control mice and mice receiving hAAT. Day-14 inguinal DLN were collected for FACS analysis. As shown in FIG. 2A, the number of B cells in the lymph nodes rose by 22.4% on average in transplanted mice, compared to control non-grafted mice. However, hAAT-treated mice displayed a 54.2% decrease on average of B cells from skin transplanted untreated mice. Surface levels of CD40 significantly increased compared to non-grafted mice, and then reduced with hAAT treatment (FIG. 2A).

[0090]DLN RT-PCR analysis was performed 3 days after transplantation. FIG. 2B depicts relative changes in specific transcript numbers. While DLN CD40, IL-6 and IL-10 transcript levels did not increase after xenotransplantation at this time point, CD86 displayed a significant...

example 3

Islet Xenotransplant Survival is Extended under hAAT and Temporary T Cell Depletion Combination

[0091]Since monotherapy with hAAT appears to have allowed an uninterrupted xeno-response, we sought to examine the combination of hAAT treatment with a technique for modifying xenoimmunity, namely, temporary T cell depletion.

[0092]Debulking therapy was examined alone and in combination with hAAT (FIG. 3A-E and FIG. 4). Recipient mice were treated with single-dose anti-CD8 / CD4 depleting antibodies, with or without hAAT (n=5-7 per group). According to circulating mouse CD45+CD3+ follow-up (FIG. 3A, representative result), mice injected with depleting antibodies exhibited a decrease in the relative number of circulating T cells and a spontaneous return to normal lymphocyte levels after a period of approximately two weeks.

[0093]As shown in FIG. 3B, animals treated by debulking therapy (DB) displayed a delay in xenograft rejection (days 28, 31, 31, 33, 33, 40, 52). In contrast, combined debulki...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
pathological immune reactivityaaaaaaaaaa
Login to View More

Abstract

The present invention provides compositions and methods for the prevention and treatment of aggressive immune processes to life-saving grafts, such as xenograft rejection, and for attenuating host responses in transplantation of tissues, cells and organs. More specifically, the compositions and methods of the present invention relate to combined therapies comprising treatment of alpha-1-antitrypsin (AAT) and temporary T-cell depletion including but not limited to anti-CD4 and anti-CD8 antibodies.

Description

FIELD OF THE INVENTION[0001]The present invention relates to compositions and methods for the prevention and treatment of graft rejection, including xenograft rejection, and for attenuating host responses in transplantation of cells, pancreatic islets, tissues and organs. More specifically, the compositions and methods of the present invention relate to combined therapies comprising treatment of alpha-1-antitryp sin and temporary T-cell depletion in the graft recipient.BACKGROUND OF THE INVENTION[0002]Transplantation systems such as organ transplantations have become important, effective and at times the sole therapies for many life-threatening end-stage diseases. However, injurious immune responses are still the major barrier for successful transplantation. This is manifested in irreversible and life-threatening graft failure (host-versus-graft response, or HVG) or pathological immune reactivity of bone-marrow transplants graft-versus-host disease (GVHD). Importantly, current immun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K38/57
CPCA61K38/57A61K39/3955A61K39/39541A61K38/14A61K38/191A61K38/217A61P37/06A61K2300/00A61K35/39A61K39/395A61K2039/505C07K16/40
Inventor LEWIS, ELI
Owner BEN GURION UNIVERSITY OF THE NEGEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com